{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"description":"Number of participants with adverse events as a measure of safety and tolerability","groups":[{"description":"Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.","id":"OG000","title":"Lenalidomide"},{"description":"Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"6 weeks","title":"Safety","type":"SECONDARY","unitOfMeasure":"participants"}